[Treatment of type I diabetes mellitus with biosynthetic human insulin]. 1985

M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007330 Insulin Antibodies Antibodies specific to INSULIN. Antibodies, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
May 1983, MMW, Munchener medizinische Wochenschrift,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
January 1994, Schweizerische medizinische Wochenschrift. Supplementum,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
January 1985, The Netherlands journal of medicine,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
November 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
January 1993, Problemy endokrinologii,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
January 1994, Problemy endokrinologii,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
February 2001, Annals of internal medicine,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
June 1992, Endocrinology and metabolism clinics of North America,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
June 1985, Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde,
M T Guagnano, and M Anichini, and F Della Loggia, and A Renzetti, and E Vitacolonna, and S Sensi
June 1987, Medizinische Klinik (Munich, Germany : 1983),
Copied contents to your clipboard!